Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc (ALXN)
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.alexion.com/investor-relations
Company Research
Source: Business Wire
– European Commission decision anticipated in June 2020 –– If approved, ULTOMIRIS has the potential to become the new standard of care in Europe for the treatment of atypical hemolytic uremic syndrome (aHUS) – – aHUS is an ultra-rare disease which may progressively damage the kidney and other organs1,2 – BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization in the European Union for ULTOMIRIS® (ravulizumab) for the treatment of patients with a body weight of 10 kg or above with atypical hemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received SOLIRIS® (eculizumab) for at least 3 months and have evidence of response to eculizumab.Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and b
Show less
Read more
Impact Snapshot
Event Time:
ALXN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXN alerts
High impacting Alexion Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics